Status:
COMPLETED
Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Neuromuscular Diseases
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Des vaccins sont désormais disponibles en France, dont le vaccin Moderna COVID-19 qui est basé sur la technologie des ARNm. La séquence génétique qu'il contient code pour la protéine Spike (S) de l'en...
Detailed Description
COVID-19 is linked to SARS-CoV-2, a new coronavirus that can lead to death. Some neuromuscular patientsare considered at risk for various reasons: cardiomyopathy or rhythm and/or conduction disorder, ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- \- For patients with severe neuromuscular disease:
- Adult over 18
- Person with a defined severe neuromuscular pathology by a modified Rankin score ≥ 4
- Person supported at the YDK pole
- Person who has received vaccination with the Moderna vaccine, in the quadriceps or deltoid
- Non-objection of the patient and/or his legal representative to the participation in the study
- For patients in the negative control group :
- Non-objection of the patient to the storage and use in the framework of the CANNEMUSS study of these blood samples from the routine care.
- Patient having had a blood sample taken as part of the treatment for virological analysis before anti-COVID 19 vaccination.
- Patient matched in sex and age to a patient included in the study CANNEMUSS.
- For patients in the positive control group :
- Non-objection of the patient to the storage and use in the framework of the CANNEMUSS study of these blood samples from the routine care.
- Patient having had a blood sample taken as part of the treatment for virological analysis following infection with the omicron variant.
- Exclusion Criteria for patients with neuromuscular disease severe
- Person with symptomatic infection with SARS-CoV-2 proven by a positive PCR
- Person with Amyotrophic Lateral Sclerosis
Exclusion
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05353738
Start Date
September 1 2021
End Date
September 1 2022
Last Update
October 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Bordeaux
Bordeaux, France, 33 000